Buy Selank Powder Peptide | 10MG

Clinical studies on selank show its potential for treating anxiety disorders. Research reports surrounding animal studies have found that selank has the ability to restore adrenaline, norepinephrine, and dopamine functions.

Selank comes in a 10 mg vial. It is a white lyophilized powder meant for studies and research purposes. This peptide is an artificial version of a natural tetrapeptide, called tuftsin.

Application:	potential to restore adrenaline, norepinephrine, & dopamine functions
CAS:	129954-34-3
Molecular Weight:	751.89 Da (g/mol)
Chemical Formula:	C33H57N11O9
Chemical Name:	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Synonyms:	Selanc
Storage:	Minimize open air exposure, store in a cool dry place.
Stability:	2 years
Purity:	99%
Solubility:	Soluble to water at rate of 1mg/ml
Physical Form:	fine powder in glass vial
Specifications:	10mg vial
Terms:	The products we offer are intended for laboratory research use only. You will need to purchase Bacteriostatic water separately.

What is Selank?

Selank is a synthetic peptide, initially developed in Russia as a potential treatment for anxiety disorders. It belongs to the class of anxiolytic (anxiety-reducing) drugs known as nootropics, which are substances purported to enhance cognitive function and alleviate stress without causing sedation or other adverse effects associated with traditional anxiolytics.

Selank is derived from the naturally occurring tetrapeptide tuftsin, which plays a role in modulating immune responses and regulating various physiological processes. Tuftsin consists of four amino acids: threonine, l-lysine, l-proline, and l-arginine. Selank is a modified version of tuftsin, with additional modifications aimed at enhancing its therapeutic properties, including increased stability and prolonged duration of action.

Due to its potential anxiolytic and cognitive-enhancing effects, Selank has gained attention in the field of neuroscience and psychopharmacology. Research suggests that Selank may exert its effects through modulation of neurotransmitter systems, particularly the gamma-aminobutyric acid (GABA) and serotonin pathways, which are implicated in the regulation of mood, anxiety, and stress responses.

Structure of Selank and Amino Acid Breakdown

The chemical structure of Selank consists of a sequence of eight amino acids, which are the building blocks of proteins and peptides. These amino acids are: Thr (Threonine), Lys (L-lysine), Pro (L-proline), Arg (L-arginine), Gly (Glycine), Pro (L-proline), Pro (L-proline), and Ala (L-alanine). 

Each amino acid in the sequence contributes to the overall structure and function of Selank:

• Threonine (Thr): Provides structural integrity and stability to the peptide.
• L-lysine (Lys): Plays a role in cellular metabolism and protein synthesis.
• L-proline (Pro): Contributes to the conformational stability of Selank.
• L-arginine (Arg): May enhance blood flow and neurotransmitter release in the brain.
• Glycine (Gly): Acts as a neurotransmitter precursor and may have calming effects on the central nervous system.
• L-alanine (Ala): Enhances the stability and bioavailability of Selank.

These amino acids work synergistically to confer Selank with its anxiolytic and cognitive-enhancing properties.

Image: Side by side of tuftsin (naturally produced by the body) and selank (synthetic version of tuftsin).

Mechanism of Action for Selank

The precise mechanism of action underlying Selank’s effects is not fully understood, but it is believed to involve modulation of various neurotransmitter systems in the brain. Selank is thought to exert its anxiolytic effects through interaction with receptors for gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system.

Clinical Trials | Selank

Selank for Anxiety

For the purpose of testing the abilities of selank to reduce stress, male wistar rats were used in the noted clinical trial. In this trial, the anxiolytic activity of both selank and diazepam were tested against a lack of stressors and unpredictable chronic mild stress. The final data obtained from this particular trial concluded that selank was the most effective in “reducing anxiety in unpredictable chronic mild stress conditions”[1].

Memory & Learning with Selank

A clinical trial on outbred rats receiving ethanol as their only source of fluid was used in an effort to analyze the effects of selank on memory impairment. The rats that received the selank treatments intraperitoneally “produced a cognitive-stimulating effect in 9 months rats not exposed to ethanol and prevented the formation of ethanol-induced memory and attention disturbances developing during alcohol withdrawal”[2]. The results from this specific clinical trial published in 2019 indicates selank has positive effects on age-related memory.

Selank Monoamines and Their Metabolites in Mice

The study investigated the impact of the heptapeptide selank on neurotransmitter monoamines and their metabolites in the brain structures of BALB/C and C57Bl/6 mice during the open-field test. Interstrain differences were observed in the content of norepinephrine (NE), dopamine (DA), serotonin (5-HT), and their metabolites in various brain regions.

Notably, BALB/C mice exhibited higher levels of 5-HT and its metabolite 5-oxyindolacetic acid in the hippocampus compared to C57Bl/6 mice. Selank administration (0.3 mg/kg) led to an increase in NE levels in the hypothalamus of both mouse strains. However, selank produced divergent effects on DA metabolites: concentrations of dioxyphenylacetic and homovanillic acids increased in the frontal cortex and hippocampus of C57Bl/6 mice but decreased in BALB/C mice. Additionally, selank induced a decrease in 5-HT and 5-HIAA levels in the hippocampus of BALB/C mice but did not affect these parameters in C57Bl/6 animals.

The results suggest the selectivity of selank’s anxiolytic effects based on the observed differential impact on neurotransmitter levels in the two mouse strains. [3]

Influence of Selank on the Level of Cytokines in Social Stress

The study aimed to explore the impact of Selank on cytokine levels in animals experiencing “social” stress. The chosen model involved confrontations between male rats to induce sensory stress. Rats were divided into three groups: intact males, animals subjected to 20 days of stress (sensory contact), and a group receiving intraperitoneal Selank during the 20-day stress period.

Results indicated a statistically significant increase in the levels of pro-inflammatory cytokines IL-1β, IL-6, and TGF-β1 in the serum of stressed animals. Although there was a tendency to decrease IL-4 concentration and increase TNF-α, these changes were not statistically significant. Selank administration during stress showed a notable effect, causing a decrease in IL-1β and IL-6 concentrations, restoration of IL-4 levels, and suppression of TGF-β1 and TNF-α production.

In conclusion, Selank demonstrated the ability to reduce the concentration of IL-1β, IL-6, and TNF-α, as well as TGF-β1, nearly reaching control values in the context of “social” stress. The study suggests the potential stress-protective activity of Selank and highlights the need for further research on cytokines’ role in stress-induced changes for optimal correction tools. [5]

Use of Selank to Correct Measures of Integrative Brain Activity and Biogenic Amine Levels in Rat Model

The study explored the impact of Selank, a heptapeptide with the active component Thr-Lys-Pro-Arg-Pro-Gly-Pro, on behavior and neurotransmitter levels in adult rats exposed to antenatal hypoxia during days 14–16 of gestation. Administering Selank intraperitoneally resulted in significant improvements in sensory attention levels and facilitated the learning process. 

Selank also normalized investigative activity levels in the open field and hole board tests. Importantly, it restored the balance of activity between the serotonergic and noradrenergic systems in the brain. These findings suggest that Selank may be beneficial in compensating for the enduring negative effects of antenatal hypoxia on brain integrative activity and the functioning of monoaminergic transmitter systems in adult rats. [6]

Therapeutic Applications of Selank in Animal Studies

In animal studies, Selank has demonstrated promising therapeutic potential across various neurological and psychiatric conditions. Preclinical studies offer insights into its effects on animal models. Here are some key therapeutic applications observed in animal studies:

• Anxiety Disorders: Animal models of anxiety, such as the elevated plus maze and the light-dark box test, have been utilized to investigate the anxiolytic properties of Selank. Research suggests that Selank administration reduces anxiety-like behaviors in rodents, characterized by increased exploratory behavior in aversive environments and decreased stress responses.
• Cognitive Enhancement: Selank has shown cognitive-enhancing effects in animal models of cognitive impairment and neurodegenerative diseases. Studies utilizing tasks assessing learning and memory, such as the Morris water maze and novel object recognition tests, have demonstrated improvements in cognitive function following Selank administration. These effects may be mediated by modulation of neurotransmitter systems involved in memory consolidation and synaptic plasticity.
• Stress Resilience: Chronic stress exposure in animal models can lead to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and increased susceptibility to stress-related disorders. Selank has been shown to mitigate the physiological and behavioral consequences of chronic stress, including normalization of HPA axis activity, attenuation of stress-induced behavioral changes, and reduction of oxidative stress markers in the brain.
• Neuroprotection: Animal studies have highlighted the neuroprotective effects of Selank in various experimental paradigms of neurotoxicity and neurodegeneration. Selank administration has been associated with reduced neuronal damage, enhanced neuronal survival, and preservation of cognitive function in animal models of ischemic stroke, traumatic brain injury, and neurotoxin-induced neurodegeneration.
• Pain Modulation: Emerging evidence suggests that Selank may possess analgesic properties, as evidenced by its ability to attenuate pain responses in animal models of acute and chronic pain. Mechanisms underlying Selank-mediated analgesia are not fully elucidated but may involve modulation of pain processing pathways and neuroimmune interactions within the central nervous system.

Overall, animal studies provide valuable insights into the therapeutic potential of Selank across a spectrum of neuropsychiatric disorders and neurological conditions.

*Disclaimer: The selank currently listed on this site is for research use only. Not for human consumption. This product is not a drug, supplement, food or cosmetic and it may not be misused, sold, labeled or branded as such. These products are not intended to diagnose, treat, or cure any condition or disease.